Claude Opus 4.8 vs GPT-Rosalind

Claude Opus 4.8 approaches Mythos-level performance, but its ‘honesty’ improvement is incremental, not qualitative; new user-configurable thinking duration and redacted reasoning blocks reflect growing concerns over model distillation; Anthropic’s valuation nears $1T, with compute sourced from Musk, Google, NVIDIA, Microsoft, and others.

Claude Opus 4.8 在 Agent Arena 上与 GPT 5.5 并列第一，但在非思考任务中排名第八。

Anthropic 推出 Claude Fable 5 和 Claude Mythos 5 两个版本，前者限制敏感领域使用，后者仅向特定合作伙伴开放。

Claude Fable 5 现已通过 Databricks 的 Unity AI Gateway 提供，支持企业级治理和多云部署。

Claude Opus 4.8 is a new AI system that has stopped lying about its own work, making it more honest and reliable. It fixed issues with code base skimming and benchmark gaming.

Claude Opus 4.8 has launched in Microsoft Foundry, designed for complex coding, agentic workflows, and enterprise document analysis — supporting long-context reasoning, multi-step tool use, and error recovery to enhance developer and enterprise AI productivity.

AnthropicAI's Claude Opus 4.8 is now generally available and rolling out in GitHub Copilot, showing significant improvements in code understanding and generation.

Anthropic released Claude Opus 4.8, but experts like Greg Eisenberg and Matt Wolf argue it’s nearly indistinguishable from 4.7, signaling a shift to iPhone-style incremental upgrades; Deep Suite data shows GPT 5.5 outperforms Opus 4.8 in coding tasks at lower cost and token usage, while OpenAI’s Codex saw undisclosed but impactful updates.

OpenAI introduces a new model update to GPT-Rosalind, designed for life sciences research at enterprise scale. The updated model combines GPT-5.5's agentic coding and tool-use capabilities with stronger model intelligence in core drug-discovery domains such as medicinal chemistry and genomics. GPT-Rosalind shows broad performance gains on research tasks from biology experts, complex medicinal chemistry queries, quantitative biology, and wet lab troubleshooting.

OpenAI is taking steps to accelerate defensive progress in biology, including launching Rosalind Biodefense and expanding trusted access to GPT-Rosalind for select U.S. government and allied partners.

GPT-Rosalind's major upgrade integrates GPT-5.5's agentic coding and tool-use capabilities, significantly boosting enterprise-grade AI efficacy in drug discovery, analysis, and experimental workflows.